Sy­ros' shares plum­met as blood can­cer drug fails again

Sy­ros Phar­ma­ceu­ti­cals’ stock price nose­dived af­ter its last drug can­di­date flunked a tri­al in hema­to­log­i­cal ma­lig­nan­cies for the sec­ond time in re­cent months.

In a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER